Spending power
TheGrid Corporate Spending Power index would rate purchasing capacity from registry, scale and activity signals.
Spending power
Key facts
Counted staff
2
self-reported 2–10 band
Founded
2021
5 years
Legal entities
None matched
Office countries
1
1 address
Funding rounds
None on record
Company type
Privately Held
self-reported
Description
Pioneering next generation automated Micro-dissection Pathology through our highly advanced Cytomask platform. Combining patented science & technology, Cytomask platform delivers far superior diagnostic results especially for cancer patients. With pure and precise results, we open up pathways to bring about breakthroughs in cancer diagnosis & personalised treatments.
Specialties
All 5 specialties
- Biotechnology
- Diagnostics
- Pathology
- Oncology
- Microdissection
Locations
Country footprint
Show as table · Offices in 1 country
| Countries | 1 |
|---|---|
| Primary country | SG |
All codes: SG
Addresses
- SGSingapore, SingaporePrimary
Grid intelligence Members
Signals & hiring
Hiring, headcount and registry-change signals, streamed to members.
Latest signal
Hiring activity
Headcount trend
Financials
Registry-filed capital and financial indicators, standardised by TheGrid.
Paid-up capital
Fiscal period
Registered charges
Revenue
Profit / loss
FAQ
How many people work at Quantumcyte?
The record holds 2 counted staff profiles at January 2026, inside the self-reported 2–10 band.
Where does Quantumcyte have offices?
One address on record, Singapore only. Primary: Singapore.
Has Quantumcyte raised funding?
None linked to this brand.
What does Quantumcyte list as its specialties?
Five tags on the brand's own list, among them oncology, diagnostics and biotechnology.
Which companies are listed alongside Quantumcyte?
5 profiles list Quantumcyte as a peer — 62nd percentile in Biotechnology Research. It lists ten peers of its own. Waffle and Blockchain Worx list it back.